Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Inadequately Controlled Asthma
NCT01902290Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of brodalumab in asthma, sponsored by Amgen. Started May 2013; status: terminated.
02
Drugs
brodalumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01902290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01902290.